1. Home
  2. INDP vs XAIR Comparison

INDP vs XAIR Comparison

Compare INDP & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

HOLD

Current Price

$2.36

Market Cap

5.2M

Sector

Health Care

ML Signal

HOLD

Logo Beyond Air Inc.

XAIR

Beyond Air Inc.

HOLD

Current Price

$0.52

Market Cap

5.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INDP
XAIR
Founded
2000
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.2M
5.4M
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
INDP
XAIR
Price
$2.36
$0.52
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
67.6K
320.4K
Earning Date
05-11-2026
06-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
62.09
EPS
N/A
N/A
Revenue
N/A
$3,705,000.00
Revenue This Year
N/A
$122.00
Revenue Next Year
N/A
$58.15
P/E Ratio
N/A
N/A
Revenue Growth
N/A
219.67
52 Week Low
$0.27
$0.15
52 Week High
$13.24
$3.78

Technical Indicators

Market Signals
Indicator
INDP
XAIR
Relative Strength Index (RSI) 45.22 38.41
Support Level $2.36 $0.43
Resistance Level $3.11 $0.82
Average True Range (ATR) 0.41 0.06
MACD -0.07 0.01
Stochastic Oscillator 25.71 36.87

Price Performance

Historical Comparison
INDP
XAIR

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

About XAIR Beyond Air Inc.

Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.

Share on Social Networks: